Modified immune cells target HIV during cancer treatment
NCT ID NCT04975698
Summary
This study tested whether specially modified immune cells could help control HIV in patients undergoing stem cell transplants for lymphoma. Twelve HIV-positive patients with lymphoma received their own stem cells back after chemotherapy, followed by an infusion of HIV-targeting immune cells. Researchers wanted to see if this approach could reduce the hidden HIV reservoir while treating the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV ASSOCIATED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Georgetown
Washington D.C., District of Columbia, 20057, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Johns Hopkins University
Baltimore, Maryland, 21231, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering (MSKCC)
New York, New York, 10065, United States
-
Northside
Atlanta, Georgia, 30342, United States
-
University of Illinois
Chicago, Illinois, 60612, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.